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AbstrAct
background Critical illness is a leading cause of 
morbidity and mortality in sub-Saharan Africa (SSA). 
Identifying patients with the highest risk of death could 
help with resource allocation and clinical decision making. 
Accordingly, we derived and validated a universal vital 
assessment (UVA) score for use in SSA.
Methods We pooled data from hospital-based cohort 
studies conducted in six countries in SSA spanning the 
years 2009–2015. We derived and internally validated a 
UVA score using decision trees and linear regression and 
compared its performance with the modified early warning 
score (MEWS) and the quick sepsis-related organ failure 
assessment (qSOFA) score.
results Of 5573 patients included in the analysis, 2829 
(50.8%) were female, the median (IQR) age was 36 
(27–49) years, 2122 (38.1%) were HIV-infected and 996 
(17.3%) died in-hospital. The UVA score included points 
for temperature, heart and respiratory rates, systolic blood 
pressure, oxygen saturation, Glasgow Coma Scale score 
and HIV serostatus, and had an area under the receiver 
operating characteristic curve (AUC) of 0.77 (95% CI 0.75 
to 0.79), which outperformed MEWS (AUC 0.70 (95% CI 
0.67 to 0.71)) and qSOFA (AUC 0.69 (95% CI 0.67 to 0.72)).
conclusion We identified predictors of in-hospital 
mortality irrespective of the underlying condition(s) in a 
large population of hospitalised patients in SSA and derived 
and internally validated a UVA score to assist clinicians in 
risk-stratifying patients for in-hospital mortality. The UVA 
score could help improve patient triage in resource-limited 
environments and serve as a standard for mortality risk in 
future studies.
IntroductIon
In sub-Saharan Africa (SSA), critical illness in 
adults is a frequent and increasing cause of 
hospital admission and subsequent death, the 
majority of which is attributed to infection.1 
Successful outcomes from critical illness 
Key questions
What is already known about this topic?
 ► Critical illness is a frequent cause of morbidity and 
mortality in sub-Saharan Africa.
 ► Most critical care in sub-Saharan Africa takes 
place on general wards where human and material 
resources are limited.
 ► A standard method for determining mortality risk can 
assist in clinical decision making.
What are the new findings?
 ► A universal vital assessment (UVA) score was derived 
and validated in a large number of hospitalised 
patients from six countries in sub-Saharan Africa.
 ► The UVA score was created using readily available 
clinical variables and could be applied in any 
resource-limited acute care setting.
 ► The UVA score outperformed the modified early 
warning score (MEWS) and the quick sepsis-related 
organ failure assessment (qSOFA) score in predicting 
risk of death of hospitalised patients.
recommendations for policy
 ► The UVA score could assist clinicians in making 
triage decisions about appropriate level of care.
 ► The UVA score may also help clinicians identify 
patients at moderate to high risk of death who could 
benefit from further diagnostic testing to determine 
underlying causes of illness or infection.
 ► The UVA score may be useful in standardising risk of 
death of patients in future studies.
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depend on rapidly identifying deteriorating patients and 
intervening with therapies such as antimicrobials, fluid 
resuscitation and source control.2 However, intensive care 
units (ICUs) are unavailable in many district hospitals in 
SSA.3 Therefore, most critical care in SSA is administered 
on the general wards of district hospitals where diag-
nostic and therapeutic interventions are constrained.4
A better understanding of the severity of a patient’s 
illness in resource-limited environments could improve 
allocation of human and material resources, and inform 
triage decisions in settings where a higher level of care is 
available. There are few examples of early warning scores 
(EWS) guiding therapy in hospitals in Africa. Use of the 
South African Triage Score in a rural emergency depart-
ment in South Africa, in Botswana and in Somaliland 
led to undertriage and overtriage.5–7 A trial of an EWS to 
trigger nursing assessments on a surgical ward in South 
Africa showed no difference in outcomes compared 
with standard care, but a study in Uganda showed that 
targeted monitoring and resuscitation of adults with 
sepsis on admission can improve outcomes.8 9 Large 
investments in ICU infrastructure are unlikely to occur 
soon in these environments, but improved resource-ap-
propriate assessment of patients on general wards may 
improve outcomes from critical illness.
The degree of aberration in vital signs can be used 
to assess illness severity and guide therapeutic interven-
tions.10 Accordingly, vital signs have been incorporated 
into scoring systems such as the modified early warning 
score (MEWS) to identify deteriorating patients admitted 
to hospital.11 Recently, a consensus panel developed new 
definitions of sepsis that incorporated a clinically derived 
quick sepsis-related organ failure assessment (qSOFA) 
score to identify patients with infection and high risk of 
death.12 There are few EWS derived from patients in SSA 
and they were performed in small populations at single 
sites with varying performance.13 14 Therefore, we pooled 
data from hospital-based cohort studies conducted 
throughout SSA to (1) determine predictors of mortality, 
(2) create an accurate and easy-to-use universal vital 
assessment (UVA) score and 3) compare the perfor-
mance of the UVA score in predicting mortality with that 
of MEWS and qSOFA.
Methods
study design
We conducted a retrospective cohort study using pooled 
data from hospital-based cohort studies throughout 
SSA. To identify appropriate cohorts for inclusion in 
the study, we performed a systematic literature search 
using PubMed with the following medical subject head-
ings: (‘Hospital mortality’ or (‘hospitalization’ and 
‘mortality’)) and ‘Africa South of the Sahara’. We limited 
the search to adults ≥19, the years 2000–2015 and the 
English language. This search provided 423 records. We 
also found 11 records from other sources, including 9 
found from the references of the searched records and 2 
unpublished data sets offered by corresponding authors. 
Of these 434 records, we selected 28 that fulfilled our 
criteria that included patients from SSA admitted to a 
medical ward with vital sign data and mortality outcomes. 
We then contacted the corresponding author to ask 
permission to access their de-identified study database. 
All included research on human subjects was approved 
by the appropriate ethics committee and conformed to 
the principles embodied in the Declaration of Helsinki.
study population
We predefined selected variables to include in our models 
that were likely to be available in resource-limited clinical 
settings. Since we planned a comparison of the perfor-
mance of the UVA score with that of MEWS and qSOFA, 
we ensured that the variables included in these scores 
were also included in our pooled data. The variables 
in the combined data set were admission temperature, 
heart and respiratory rate, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), oxygen saturation, 
Glasgow Coma Scale (GCS) score, white blood cell (WBC) 
count, haemoglobin concentration, platelet concentra-
tion, whole blood lactate concentration, HIV serostatus, 
CD4+ T cell (CD4) count and in-hospital mortality. We 
converted alert, voice, pain, unresponsive (AVPU) and 
GCS scores to each other as needed.15 To avoid negative 
numbers and outliers in our data that likely represented 
data entry errors or spurious values, we included clinical 
data points in the combined data set if they were positive, 
within the 1st and 99th percentile of a given variable, and 
within accepted limits for GCS score (3–15) and oxygen 
saturation (≤100%). All patients included in the anal-
ysis had an outcome recorded for in-hospital mortality 
and greater than 50% of the following clinical variables: 
temperature, heart rate, respiratory rate, SBP, DBP, GCS 
and oxygen saturation.
Missing values
Missing values were handled using the k-nearest neigh-
bours single imputation method.16 In order to determine 
ORs for clinical as well as laboratory variables, we imputed 
missing data by subsets. The largest subset consisted of 
only age, sex, temperature, heart rate, respiratory rate, 
SBP, DBP, oxygen saturation, GCS score, HIV serostatus, 
CD4 count (if HIV-infected) and in-hospital mortality 
(n=5573). The other subset consisted of the same 
variables with lactate and at least one of WBC count, 
haemoglobin concentration or platelet concentration 
(n=1513). All variables except in-hospital mortality and 
HIV serostatus were imputed.
descriptive and statistical analyses
We used the χ2test for comparisons of proportions and 
the Mann-Whitney U test for comparisons of continuous 
variables to compare baseline characteristics of patients 
who did or did not die in hospital. We considered a 
two-sided p value <0.05 significant for all statistical tests. 
We used R (R Foundation for Statistical Computing, 
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Table 1 Components of UVA, MEWS and qSOFA scores
UVA MEWS qSOFA
Temperature X X
Heart rate X X
Respiratory rate X X X
Blood pressure X X X
Oxygen saturation X
Level of consciousness X X X
HIV serostatus X
MEWS, modified early warning score; qSOFA, quick sepsis-related 
organ failure assessment; UVA, universal vital assessment.
Vienna, Austria) for all analyses and used the Trans-
parent Reporting of a multivariable prediction model 
for Individual Prognosis or Diagnosis (TRIPOD) and 
Strengthening the Reporting of Observational Studies in 
Epidemiology checklists in analysing and reporting this 
study.17
We created logistic regression models for the entire 
cohort that included clinical data with and without 
HIV serostatus, and clinical plus laboratory data. We 
calculated variance inflation factors to determine multi-
collinearity. We reported ORs and validated these models 
internally using 10-fold cross-validation (TRIPOD type 
1b model study) to estimate the performance on a new 
sample of observations from the same patient population. 
The final models were evaluated using log-likelihood 
ratios. We evaluated the ability of the model to discrim-
inate in-hospital mortality using the area under the 
receiver operating characteristic curve (AUC) following 
10-fold cross-validation.
In order to create an easy-to-use clinical UVA score, 
we created a point-based scoring system. We used the 
Bayesian model averaging package in R to select the clin-
ical variables that produced the model with the minimal 
Bayesian information criterion.18 We then used the rpart 
package in R to create decision trees for each selected 
clinical variable on in-hospital mortality. For the decision 
tree analysis, we upsampled in-hospital mortality to adjust 
for the class imbalance of mortality. We then determined 
decision tree splits by selecting the complexity parameter 
that resulted in the smallest error using 10-fold cross-vali-
dation. We built a linear regression of in-hospital mortality 
on each selected variable at its decision tree split point.19 
We divided each beta coefficient in the linear regression 
model by the smallest absolute value significant beta coef-
ficient. We then assigned a point value for the variable 
range using the rounded value. We then summed points 
for each patient to create a UVA score. We compared 
the decision tree cut-offs derived from the multivariate 
logistic regression model with decision tree cut-offs that 
were adjusted after clinical interpretation. We selected 
the best UVA point-based scoring model after a compar-
ison of the performance of the candidate models.
We compared the performance of the UVA score 
with MEWS and qSOFA (table 1). MEWS was selected 
over the National Early Warning Score (NEWS) since 
supplemental oxygen, a component of NEWS, was not 
recorded in our pooled data. We assessed the perfor-
mance of the scores in the original clinical data set, as 
well as in subsets that included patients with a known HIV 
serostatus, suspected infection as the cause of admission 
and patients without a clinical diagnosis. We determined 
the optimal UVA score cut-off for sensitivity, specificity 
and positive predictive value (PPV), and determined low, 
medium and high-risk of mortality groups by creating 
UVA score cut-offs that divided the study population into 
three approximately equal groups.
results
The combined study population included 13 cohort 
studies of adult hospitalised patients from Gabon, 
Malawi, Sierra Leone, Tanzania, Uganda and Zambia 
(figure 1).9 13 14 20–29 We also included unpublished 
hospital data from patients with sepsis in Zambia (n=209) 
and patients with meningitis in Uganda (n=141) (table 2). 
This resulted in 5944 patients, a number that was reduced 
to 5573 patients after applying our data filters (figure 2). 
Of 5573 patients included in the analysis, 2829 (50.8%) 
were female, the median (IQR) age was 36 (27–49) years, 
2122 (38.1%) were HIV-infected and 996 (17.3%) did 
not survive to discharge from hospital (table 3).
In the multivariable logistic regression model, there 
was an association between in-hospital mortality and HIV 
infection (adjusted OR (aOR) 2.9, 95% CI 2.3 to 3.7) and 
increasing lactate (aOR 1.07, 95% CI 1.02 to 1.12). There 
was an inverse relationship between in-hospital mortality 
and temperature (aOR 0.85, 95% CI 0.81 to 0.9), oxygen 
saturation (aOR 0.98, 95% CI 0.97 to 0.99), GCS score 
(aOR 0.75, 95% CI 0.73 to 0.78) and haemoglobin 
concentration (aOR 0.91, 95% CI 0.87 to 0.95) (table 4). 
The AUC was highest for the clinical data alone model 
(AUC=0.74, 95% CI 0.72 to 0.76) and the clinical data 
plus known HIV serostatus model (AUC=0.78, 95% CI 
0.76 to 0.79), and lowest for the model that included 
laboratory values (AUC=0.71, 95% CI 0.68 to 0.74).
The UVA points-based scoring system was derived 
from the known HIV serostatus population, which was 
used because of the high OR for in-hospital mortality 
for HIV (table 5). The Bayesian model averaging model 
indicated that temperature, heart rate, respiratory rate, 
DBP, oxygen saturation, GCS and HIV were the vari-
ables that produced the minimal Bayesian information 
criterion. For the sake of clinical simplicity, we replaced 
DBP with SBP, the decision tree cut-off for respiratory 
rate was changed from 34 to 30 breaths/min and the 
cut-off for GCS was changed from <14 to <15.12 The AUC 
(95% CI) of the UVA score before the change was 0.75 
(0.73 to 0.77), which was not significantly different from 
the performance of the final UVA score model.
Overall, the UVA score model performed well with an 
AUC (95% CI) of 0.77 (0.75 to 0.79) and outperformed 
MEWS (AUC 0.70, 95% CI 0.68 to 0.71) and qSOFA 
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Figure 1 Study selection of pooled hospital-based cohort studies conducted in six African countries from 2009 to 2015 
included in the derivation and validation of the universal vital assessment score.
(AUC 0.69, 95% CI 0.67 to 0.72) (table 6). In hospitalised 
patients without a clinical diagnosis (n=2420), the AUC 
(95% CI) was 0.74 (0.70 to 0.78).13 14 28 The UVA score 
performed similarly in patients with clinically suspected 
infection as the cause of admission (n=3153), with an 
AUC (95% CI) of 0.75 (0.72 to 0.77).9 20–27 29 In a subset 
of patients with complete data that did not require impu-
tation (n=1348), the UVA score AUC (95% CI) was 0.77 
(0.73 to 0.80). Since pulse oximetry is not always avail-
able in resource-limited settings, we removed oxygen 
saturation from the UVA score and found that the 
performance remained similar with an AUC (95% CI) 
of 0.76 (0.74 to 0.78). To fully simulate a real-world 
application where clinical data are often incomplete, we 
tested the UVA score in the entire pooled data set with 
a mortality outcome without data imputation (n=5903) 
and found that the AUC (95% CI) for the UVA score was 
0.75 (0.73 to 0.77) compared with 0.69 (0.67 to 0.70) 
for MEWS and 0.68 (0.66 to 071) for qSOFA. Finally, 
we conducted a sensitivity analysis whereby we imputed 
either an HIV negative or positive serostatus for all 
missing HIV serostatus values (n=2171) and tested the 
UVA score. The UVA score AUC (95% CI) was 0.76 
(0.75 to 0.78) and 0.76 (0.74 to 0.78) when HIV negative 
and HIV positive serostatus were imputed, respectively.
There was a positive relationship between the UVA 
score and in-hospital mortality, and patients in the 
medium (UVA score 2–4) and high (UVA score >4) risk 
groups were 2.76 and 10.41 times more likely to die in 
hospital compared with the low risk patients (UVA score 
0–1), respectively (figures 3 and 4; table 7). A UVA score 
of 4 provided the best combined sensitivity (72%) and 
specificity (69%) along with a PPV of 33%. This outper-
formed both a MEWS score of 5, which had a sensitivity of 
72%, a specificity of 58% and a PPV of 26%, and a qSOFA 
score of 2, which had a sensitivity of 71%, a specificity of 
59% and a PPV of 27%.
dIscussIon
In this study of the largest pooled cohort of hospital-
ised adults in SSA, we found that the risk of in-hospital 
mortality could be easily calculated by a UVA score that 
incorporated values for temperature, heart rate, respi-
ratory rate, SBP, oxygen saturation (where available), 
GCS and HIV serostatus. Patients in the medium and 
high risk groups had 3-fold and 10-fold increased odds 
of death when compared with patients in the low risk 
group, respectively. Therefore, clinical application of the 
UVA score could improve triage decisions in areas where 
human and material resources are limited, allowing for 
the greatest efforts to be applied to the most critically ill 
patients. The UVA score could also be used as a standard 
measure of mortality risk in future studies.
A MEWS score ≥5 was independently associated with 
in-hospital mortality in medical and surgical patients in 
a study in Uganda, and a NEWS score of ≥7 was associ-
ated with increased mortality in patients from an ICU 
in Tanzania.30 31 However, we found that the UVA score 
performed better than MEWS perhaps due to differences 
group.bmj.com on November 2, 2017 - Published by http://gh.bmj.com/Downloaded from 
Moore CC, et al. BMJ Glob Health 2017;2:e000344. doi:10.1136/bmjgh-2017-000344 5
BMJ Global Health
Ta
b
le
 2
 
H
os
p
ita
l-
b
as
ed
 c
oh
or
t 
st
ud
ie
s 
co
nd
uc
te
d
 in
 s
ix
 A
fr
ic
an
 c
ou
nt
rie
s 
fr
om
 2
00
9 
to
 2
01
5 
co
nt
rib
ut
in
g 
to
 p
oo
le
d
 d
at
a 
fo
r 
th
e 
d
er
iv
at
io
n 
an
d
 v
al
id
at
io
n 
of
 t
he
 u
ni
ve
rs
al
 
vi
ta
l a
ss
es
sm
en
t 
sc
or
e
S
tu
d
y 
(y
ea
r)
S
it
e
In
cl
us
io
n 
cr
it
er
ia
To
ta
l, 
n
In
-h
o
sp
it
al
 
m
o
rt
al
it
y 
(%
)
A
ve
ra
g
e 
m
is
si
ng
 
cl
in
ic
al
 d
at
a 
p
er
 
p
at
ie
nt
 (%
)*
M
is
si
ng
 o
xy
g
en
 
sa
tu
ra
ti
o
n 
p
er
 
st
ud
y 
(%
)
A
ve
ra
g
e 
m
is
si
ng
 
la
b
o
ra
to
ry
 d
at
a 
p
er
 p
at
ie
nt
 (%
)†
M
is
si
ng
 
la
ct
at
e 
p
er
 
st
ud
y 
(%
)
M
is
si
ng
 H
IV
 
p
er
 s
tu
d
y 
(%
)
M
is
si
ng
 C
D
4 
p
er
 s
tu
d
y 
(%
)‡
M
is
si
ng
 
m
o
rt
al
it
y 
p
er
 
st
ud
y 
(%
)
A
d
ak
un
 
U
ga
nd
a
M
en
in
gi
tis
§
14
1
28
1
–
4
3
0
1
0
A
m
ir 
et
 a
l2
0
U
ga
nd
a
S
ep
si
s¶
20
6
31
4
–
10
1
1
32
0
A
nd
re
w
s
Z
am
b
ia
S
ep
si
s¶
20
9
41
4
–
22
5
2
18
0
A
nd
re
w
s 
et
 a
l2
1  
Z
am
b
ia
S
ep
si
s¶
10
9
62
2
–
17
–
0
17
0
A
um
a 
et
 a
l2
2
U
ga
nd
a
S
ep
si
s*
*
21
6
19
2
–
3
6
22
0
0
H
us
on
 e
t 
al
23
 
G
ab
on
S
ep
si
s†
†
38
2
4
2
–
2
–
0
17
0
Ja
co
b
 e
t 
al
24
 
U
ga
nd
a
S
ep
si
s¶
38
8
23
2
–
7
49
16
1
2
Ja
co
b
 e
t 
al
9
U
ga
nd
a
S
ep
si
s¶
42
7
24
4
4
5
2
0
1
1
M
aj
w
al
a 
et
 a
l2
5  
U
ga
nd
a
M
en
in
gi
tis
§
14
5
31
2
–
60
2
0
0
0
O
p
io
 e
t 
al
13
U
ga
nd
a
H
os
p
ita
lis
ed
‡‡
16
69
7
18
22
–
–
66
-
0
R
ot
h 
et
 a
l2
6
S
ie
rr
a 
Le
on
e
Fe
ve
r§
§
42
9
19
13
–
87
–
94
-
0
R
ub
ac
h 
et
 a
l2
7  
Ta
nz
an
ia
Fe
ve
r¶
¶
40
3
11
1
1
2
–
3
5
1
R
yl
an
ce
 e
t 
al
28
Ta
nz
an
ia
H
os
p
ita
lis
ed
‡‡
70
9
11
5
15
–
–
–
–
0
S
se
ki
to
le
ko
 e
t 
al
29
 
U
ga
nd
a
S
ep
si
s*
*
15
0
30
1
–
2
0
13
-
2
W
he
el
er
 e
t 
al
14
 
M
al
aw
i
H
os
p
ita
lis
ed
‡‡
36
1
23
1
0
–
–
19
-
2
*C
lin
ic
al
 d
at
a 
in
cl
ud
e 
te
m
p
er
at
ur
e,
 h
ea
rt
 r
at
e,
 r
es
p
ira
to
ry
 r
at
e,
 s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 d
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
an
d
 G
la
sg
ow
 C
om
a 
S
ca
le
.
†L
ab
or
at
or
y 
d
at
a 
in
cl
ud
e 
w
hi
te
 b
lo
od
 c
el
l c
ou
nt
, h
ae
m
og
lo
b
in
 c
on
ce
nt
ra
tio
n 
an
d
 p
la
te
le
t 
co
nc
en
tr
at
io
n.
‡C
D
4 
co
un
ts
 a
re
 o
nl
y 
re
p
or
te
d
 fo
r 
H
IV
-i
nf
ec
te
d
 p
at
ie
nt
s.
§A
d
m
itt
ed
 w
ith
 a
 c
lin
ic
al
 d
ia
gn
os
is
 o
f m
en
in
gi
tis
.
¶
A
d
m
itt
ed
 w
ith
 a
 c
lin
ic
al
 d
ia
gn
os
is
 o
f s
ev
er
e 
se
p
si
s 
d
efi
ne
d
 a
s 
sy
st
em
ic
 in
fla
m
m
at
or
y 
re
sp
on
se
 s
yn
d
ro
m
e 
w
ith
 s
us
p
ec
te
d
 in
fe
ct
io
n 
an
d
 o
rg
an
 d
ys
fu
nc
tio
n.
**
A
d
m
itt
ed
 w
ith
 a
 c
lin
ic
al
 d
ia
gn
os
is
 o
f s
ep
si
s 
d
efi
ne
d
 a
s 
sy
st
em
ic
 in
fla
m
m
at
or
y 
re
sp
on
se
 s
yn
d
ro
m
e 
w
ith
 s
us
p
ec
te
d
 in
fe
ct
io
n.
††
A
d
m
itt
ed
 w
ith
 a
 t
em
p
er
at
ur
e 
≥3
8 
or
 <
36
°C
 a
nd
 a
t 
le
as
t 
on
e 
ot
he
r 
sy
st
em
ic
 in
fla
m
m
at
or
y 
re
sp
on
se
 s
yn
d
ro
m
e 
cr
ite
rio
n.
‡‡
A
d
m
itt
ed
 w
ith
 a
cu
te
 il
ln
es
s 
to
 a
 m
ed
ic
al
 w
ar
d
.
§§
A
d
m
itt
ed
 w
ith
 s
ub
je
ct
iv
e 
fe
ve
r 
or
 o
r 
ha
d
 a
 d
oc
um
en
te
d
 t
em
p
er
at
ur
e 
≥3
8°
C
 w
ith
in
 2
4 
ho
ur
s 
of
 a
d
m
is
si
on
.
¶
¶
A
d
m
itt
ed
 w
ith
 a
 t
em
p
er
at
ur
e 
≥3
8.
0°
C
.
group.bmj.com on November 2, 2017 - Published by http://gh.bmj.com/Downloaded from 
6 Moore CC, et al. BMJ Glob Health 2017;2:e000344. doi:10.1136/bmjgh-2017-000344
BMJ Global Health
Figure 2 A flow chart of patients pooled from hospital-based cohort studies conducted in six African countries from 2009 to 
2015 included in the derivation and validation of the universal vital assessment score.
in age, chronic illness, respiratory compromise and HIV 
prevalence between the derivation cohorts. The impor-
tance of severity of illness scores in patients with infection 
was recently highlighted by the new consensus sepsis-3 
definitions that incorporated mortality risk scores 
including qSOFA that were derived from large data sets 
from North America and Europe.12 Due to the clinical 
aspects of the score, qSOFA was also suggested as being 
useful in resource-limited settings.12 32 However, qSOFA 
performed poorly in comparison to the UVA score 
in our cohort including notably in subsets of patients 
with suspected infection. In contrast, the UVA score 
had an AUC of 0.77, which was similar to the AUC of 
qSOFA (0.80) in the original sepsis-3 derivation cohort, 
and maintained its high performance in patients with 
suspected infection.12 Accordingly, the UVA score should 
be prospectively evaluated for use in similar environments 
to identify patients at highest risk of in-hospital mortality 
including infected patients with probable sepsis.
Vital sign assessment is the cornerstone of monitoring 
critically ill patients. In sophisticated ICUs, patients are 
continually monitored for changes in vital signs that 
might indicate a change in clinical status. This level of 
monitoring is generally not possible in resource-lim-
ited environments where patients are likely to have 
vital signs assessed only once per day.33 However, even a 
single deranged vital sign value signalled clinical deteri-
oration in an ICU in Tanzania and increasing numbers 
of deranged values increased the odds of mortality.30 A 
subsequent treatment algorithm based on abnormal vital 
signs improved targeted clinical responses and mortality 
outcomes for hypotensive patients.34 Since the UVA score 
provides a vital assessment across six clinical variables 
plus HIV serostatus, the information gathered is more 
nuanced and therefore provides additional clinical infor-
mation about a patient’s risk of death. It is possible that 
iterative evaluations of the UVA score in hospitalised 
patients could guide therapeutic interventions.
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Table 3 Population characteristics of patients pooled from hospital-based cohort studies conducted in six African countries 
from 2009 to 2015 according to outcomes
Variable
Overall
(n=5573)
Survived
(n=4607)
Died in-hospital
(n=966) p
Female, n (%) 2829 (50.8) 2323 (50.4) 506 (52.4) 0.27
Age (years), median (IQR) 36 (27–49) 36 (26–50) 36 (29–46) 0.20
Temperature (°C), median (IQR) 37.4 (36.3–38.5) 37.4 (36.3–38.5) 37.6 (36.2–38.4) 0.36
Heart rate (bpm), median (IQR) 100 (85–120) 100 (84–116) 110 (92–128) <0.001
Respiratory rate (brpm), median (IQR) 26 (22–32) 24 (20–32) 30 (24–40) <0.001
SBP (mm Hg), median (IQR) 100 (90–120) 100 (90–120) 90 (80–110) <0.001
DBP (mm Hg), median (IQR) 62 (55–80) 65 (60–80) 60 (50–70) <0.001
Oxygen saturation (%), median (IQR) 96 (94–98) 96 (94–98) 96 (93–98) <0.001
GCS score, median (IQR) 15 (15–15) 15 (15–15) 15 (13–15) <0.001
HIV-infected, n (%) 2122 (38.1) 1537 (33.4) 585 (60.1) <0.001
CD4 (cells/μL), median (IQR) 72 (23–156) 79 (28–175) 46 (14–112) <0.001
WBC (103/μL), median (IQR) 6.0 (3.7–9.7) 6.1 (3.9–9.7) 5.6 (3.1–9.7) 0.003
Haemoglobin (g/dL), median (IQR) 10.1 (7.8–12.2) 10.4 (8.1–12.5) 8.7 (6.9–11.2) <0.001
Platelets (103/μL), median (IQR) 180 (105–270) 188 (113–275) 159 (81–256) <0.001
Lactate (mmol/L), median (IQR) 3.5 (2.4–4.9) 3.3 (2.4–4.5) 4.2 (2.7–6.1) <0.001
bpm, beats per minute; brpm, breaths per minute; CD, cluster of differentiation; DBP, diastolic blood pressure; GCS, Glasgow Coma Scale; 
SBP, systolic blood pressure; WBC, white blood cell concentration.
Although fever suggests infection, we found an inverse 
relationship between temperature and mortality in this 
cohort of patients. This finding is consistent with other 
observational studies that showed that hypothermia is 
associated with poor outcomes in critically ill patients. 
For example, in one ICU study, patients with septic shock 
had a higher mortality if they were hypothermic than if 
they were febrile.35 In another ICU study, there was an 
increase in mortality rate with increasing severity of hypo-
thermia, but fever at presentation was not associated with 
mortality.36 Additionally, severe hypothermia increased 
the risk of developing ICU-acquired infection in a study 
of ICU patients in France.37 Meanwhile, fever may afford 
host protection through increased immune function 
from production of heat shock proteins, inhibition 
of micro-organism growth and increased antimicro-
bial effectiveness.38 In patients with sepsis in Uganda, a 
temperature <35.5°C was associated with mortality, but a 
temperature of >37.5°C was not.9
Oxygen saturation is also a component of the UVA 
score. In a study from Rwanda, the prevalence of hypox-
aemia defined as oxygen saturation <90% in ward patients 
was 12% with an associated mortality of 49%, which was 
similar to the 47% patient mortality in the ICU.39 Given 
the high mortality associated with hypoxaemia, partic-
ularly in patients with sepsis, it is important to identify 
patients with low oxygen saturation.21 Fortunately, pulse 
oximetry devices are increasingly available in resource-lim-
ited settings through such efforts as the Global Pulse 
Oximetry Project.40 Acknowledging that pulse oximetry 
remains unavailable in some resource-limited settings, 
we determined that the UVA score performed well even 
without including oxygen saturation. However, when 
feasible, measuring a patient’s oxygen saturation may 
provide additional information about their mortality 
risk and prompt administration of supplemental oxygen 
where it is available.
Decreasing GCS was a strong predictor of in-hospital 
mortality. A GCS less than 15 was assigned the highest 
point value in the UVA score and was sufficient to place 
a patient in at least a medium mortality risk category. 
This is congruent with prior studies in resource-rich 
and resource-limited settings. AVPU and GCS scores 
were included in MEWS and qSOFA, which are in use in 
North America and Europe.11 12 A poor Karnofsky Perfor-
mance Score, a measure of functional status, was also 
strongly associated with early and late mortality in septic 
patients hospitalised in Uganda.24 Similarly in another 
study from Uganda, patients who were able to ambulate 
on admission had a 60-day mortality of 5% compared 
with 25% if they had an unstable gait, or 50% if they 
were bedridden.41 In Ugandan septic patients, GCS and 
mid-upper arm circumference were independently asso-
ciated with mortality even if patients were successfully 
resuscitated to lactate clearance in the first 6 hours of 
treatment.20 Our findings in this study further support 
that any change in level of consciousness or functional 
status should prompt evaluation and monitoring in 
patients admitted to hospital in SSA.
Adding HIV serostatus considerably improved the 
performance of the clinical logistic regression model 
and was also a feature of the UVA score. Although there 
is a link between HIV infection and chronic cardiovas-
cular diseases, data regarding the role of HIV infection 
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Table 5 Clinical variables and their cut-offs for the 
universal vital assessment point-based scoring model
Points
Variable 0 1 2 3 4
Temperature (°C) ≥36 <36
Heart rate (bpm) <120 ≥120
Respiratory rate 
(brpm)
<30 ≥30
SBP (mm Hg) ≥90 <90
Oxygen 
saturation (%)
≥92 <92
GCS score 15 <15
HIV infection No/unknown Yes
bpm, beats per minute; brpm, breaths per minute; GCS, Glasgow 
Coma Scale; SBP, systolic blood pressure.
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in mediating the physiological response to acute illness 
including infection are scant.42 Therefore, we are not 
aware of a direct connection between HIV infection and 
vital sign changes during an acute illness. It is more likely 
that the importance of HIV infection as a predictor of 
mortality reflects underlying immunosuppression and 
chronic illness. Unfortunately, despite increasing avail-
ability of antiretroviral therapy throughout the time 
period of our pooled data (2009–2015), CD4 counts have 
remained low for HIV-infected patients in SSA at the time 
of presentation to care and treatment.43
In our study, the median CD4 count was very low for all 
patients included in the HIV-infected regression model, 
making it difficult to use CD4 count to discriminate 
between those who survived or died as they were likely to 
have a similarly high risk for opportunistic infections such 
as tuberculosis and associated mortality. Several studies 
from SSA have identified disseminated tuberculosis as 
a leading cause of infection and mortality in hospital-
ised HIV-infected patients.44 Wasting, as measured by a 
reduced mid-upper arm circumference, is also associated 
with both HIV infection and mortality in SSA, but was not 
fully captured in our pooled data.20 Hospitalised HIV-in-
fected patients are also likely to have low functional status 
and be less likely to be ambulatory.24 41 Taken together, 
the association between HIV infection, disseminated 
tuberculosis, wasting and low functional status likely 
contributes to a high prevalence of mortality in hospital-
ised patients in SSA.
We envision the UVA score being useful both as a 
screening tool for patients admitted to hospital and as 
a tool to identify patients on the ward who are deteri-
orating and may require additional investigation and 
treatment. A UVA score of 4 provided optimal sensitivity, 
specificity and PPV for mortality, but we expect clinicians 
will determine the UVA score threshold that works best 
for their needs and patient population. For example, the 
UVA score PPV will change depending on the prevalence 
of mortality in the patient population. Since the UVA 
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Figure 3 The frequency and associated mortality of universal vital assessment (UVA) scores for all patients pooled from 
hospital-based cohort studies conducted in six African countries from 2009 to 2015.
Figure 4 Adjusted ORs with 95% CIs for in-hospital mortality associated with universal vital assessment (UVA) score point 
values for patients pooled from hospital-based cohort studies conducted in six African countries from 2009 to 2015.
score was built on admission data, prospective validation 
studies should incorporate repeated measures to deter-
mine how UVA score trends predict mortality. Thereafter, 
depending on institutional resources, prospective evalua-
tion of UVA score-based interventions such as additional 
diagnostic testing, increased monitoring or treatment 
algorithms could take the form of a simple before-and-
after study or ideally more sophisticated study designs, 
including a randomised cluster study which can account 
for confounders and control for the effect of time.45 A 
mixed-methods approach that includes a quantitative and 
qualitative data analysis could also be useful to evaluate 
adherence to clinical interventions and the processes of 
implementation of an EWS that are unique to settings in 
SSA.46
There are several limitations to this study, including its 
retrospective design. Additionally, we only conducted our 
search for English-language papers in PubMed, so it is 
possible we missed additional relevant data due to selec-
tion or publication bias. We combined heterogeneous 
data from studies conducted over a long period of time 
with different enrolment criteria and patient treatments, 
and only included admission data in order to develop 
a UVA score, which may have led to case ascertainment 
bias. Larger data sets from individual studies may have 
biased the results of our analyses of the complete cohort. 
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Table 7 Universal vital assessment score risk categories 
for patients pooled from hospital-based cohort studies 
conducted in six African countries from 2009 to 2015
Risk category 
(score) n (%) Deaths (%) OR (95% CI)
Low (0–1) 2055 (36.9) 118 (5.7) Reference
Medium (2-4) 2119 (38) 305 (14.4)
2.76 (2.22 to 
3.46)
High (>4) 1399 (25.1) 543 (38.8)
10.41 (8.43 to 
12.96)
However, creating a reliable UVA score from different 
populations recruited in different settings throughout 
SSA could be considered a strength of this work. Data 
were not complete for each data set, which could have also 
biased our results. Since omitting patients with missing 
variables from our analysis would reduce our sample 
size and power, we imputed missing values. Differences 
between sites with large amounts of missing data, which 
required imputation, were therefore diminished. Many 
of the patients in this cohort did not have a recorded 
clinical diagnosis, so it is possible that the performance 
of the UVA score may vary in different clinical subsets. 
Importantly, the UVA score performed well in a large 
subset of patients with suspected infection, suggesting it 
is useful in identifying patients with sepsis. Finally, future 
studies are required to determine the generalisability of 
the UVA score.
conclusIon
We derived and internally validated a UVA score to 
assist clinicians in risk-stratifying patients for in-hos-
pital mortality in SSA. The UVA score outperformed 
MEWS and qSOFA in our pooled data set but should be 
prospectively studied and externally validated in similar 
environments.32 The UVA score could assist clinicians in 
making triage decisions about the appropriate level of 
care required for a patient. It may also help clinicians 
identify patients at moderate to high risk of death that 
could benefit from further diagnostic testing to determine 
underlying causes of illness or infection. Additionally, the 
UVA score may be useful in standardising risk of death 
of patients in future studies. Such future studies could 
employ the UVA score iteratively in order to test its ability 
to guide daily risk of mortality and clinical decisions, and 
assess impact on patient outcomes.
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